NCT01434316: Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

NCT01434316
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: TNBC patients (regardless of BRCA status) are eligible for this study- see trial for details of cohorts; HER2+ & HR++/HER2-neg patients are eligible for the safety cohort, but must have a germline BRCA1/2 mutation- if only a somatic BRCA1/2 mutation is present, patient must speak with principal investigator
Exclusions: 
https://clinicaltrials.gov/show/NCT01434316

Comments are closed.

Up ↑